Arthroscopic meniscal procedures are the most commonly performed orthopaedic procedure in the U.S. affecting 15% of Americans ages 10-65 years. Meniscus injury is also known to increase the risk of posttraumatic osteoarthritis (PTOA). The current randomized clinical trial will test a novel intervention after meniscal repair that combines an oral senolytic fisetin and real-time biofeedback program to restore joint loading and subsequent return to activity.

开始日期2025-07-01

申办/合作机构

University of Kentucky

NCT06796374

/ Not yet recruitingN/AIIT

A Comparison of Fisetin Kinetics in Young and Old Adults - FISEKIN-1

This study investigates the differences in the kinetic parameters of fisetin in two cohorts of healthy volunteers:
Cohort 1) volunteers aged 18-30 years (n = 40) Cohort 2) volunteers aged 65 years or older (n = 40)
The purpose of this study is:
1. To describe the fisetin kinetics after a single dose oral administration in older age.
2. To compare the fisetin kinetics after a single dose oral administration in old and young age.
FISEKIN-1 is designed as a four-arm study protocol. As well as two different age groups (18-30 years vs. 65 years and older), we want to compare fisetin kinetic parameters in two different fisetin formulations and dosages :
Arm 1) 100 mg fisetin (1x 1 capsule), cohort 1: young age Arm 2) 100 mg fisetin (1x 1 capsule), cohort 2: old age Arm 3) 1000 mg fisetin + 200 mg quercetin (2x 1 softgel capsule), cohort 1: young age Arm 4) 1000 mg fisetin + 200 mg quercetin (2x 1 softgel capsule), cohort 2: old age

开始日期2025-02-01

申办/合作机构

University of Greifswald

NCT06431932

/ Not yet recruiting临床1/2期IIT

Pharmacokinetics, Safety, and Efficacy of Fisetin - A Phase I and Pilot Phase IIa Study

The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation. Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models.
We will conduct a clinical trial in healthy volunteers and older patients with multiple chronic diseases. The participants will receive fisetin or placebo for two days, after which they will be examined at regular intervals for up to three months. We will investigate how fisetin is absorbed and metabolized by the body, and whether fisetin is safe. We will also identify methods to best measure the effect of fisetin on chronic inflammation, senescent cells, and general health.

开始日期2025-01-01

申办/合作机构

Hvidovre University Hospital

[+2]

100 项与漆黄素相关的临床结果

登录后查看更多信息

100 项与漆黄素相关的转化医学

登录后查看更多信息

100 项与漆黄素相关的专利（医药）

登录后查看更多信息

3,460

项与漆黄素相关的文献（医药）

2025-12-01·MOLECULAR BIOLOGY REPORTS

Fisetin mitigates cisplatin-induced peripheral neuropathy: a behavioral and immunohistochemical study

Article

作者: Çevik, Sena ; Yilmaz, Şenay Görücü ; Adıgüzel, Cansel ; Yildirim, Caner ; Bal, Ramazan

BACKGROUND:

Cisplatin (CIS), a commonly used chemotherapeutic drug, often causes peripheral neuropathy, considerably affecting patients' quality of life. The present study investigated the neuroprotective effects of fisetin, a natural flavonoid with antioxidant and anti-inflammatory features, in a rat model of cisplatin-induced peripheral neuropathy.

METHODS AND RESULTS:

Male Wistar rats were divided into six groups: sham, neuropathy (CIS, 3 mg/kg, 5 weeks), fisetin treatment (CIS + 10 mg/kg and CIS + 20 mg/kg), and drugs control groups (10 mg/kg and 20 mg/kg fisetin alone). Behavioural experiments were conducted to evaluate motor coordination and sensory function, electrophysiologically measured nerve conduction velocity (NCV). Gene expression studies were conducted for NF-kB and GPX4 to investigate oxidative stress and inflammation. Finally, confocal microscopy studies were used to evaluate the structure of the sciatic nerve. Cisplatin induced motor impairments, sensory dysfunction, mechanical allodynia, diminished nerve conduction velocity, myelin deterioration (decreased MBP), and increased neuroinflammation (elevated GFAP and NF-kB, decreased GPX4). Fisetin, specifically at a dose of 10 mg/kg, markedly enhanced motor coordination, sensory thresholds, NCV, maintained myelin integrity, reduced glial activation, and restored oxidative and inflammatory balance by elevating GPX4 levels and decreasing NF-kB expression.

CONCLUSIONS:

These results highlight fisetin's potential as a therapeutic agent for cisplatin-induced neuropathy, emphasising its role in restoring molecular, structural, and functional integrity within the peripheral nervous system.

2025-07-01·BIOCHEMICAL PHARMACOLOGY

NUF2 activated by YY1 promotes prostate cancer malignancy via p38/MAPK signaling axis and serves as a therapeutic target

Article

作者: Liu, Yongqiang ; Ding, Li ; Zou, Libin ; Yang, Bin ; Liu, Ji ; Luo, Wentao ; Xu, Jing ; Guo, Hanxu ; Hao, Yajuan ; Yu, Yang ; Jin, Chengqi

Prostate cancer (PCa) is one of the most prevalent malignancies in the male urogenital system. Despite extensive research into its mechanisms of initiation and progression, the full scope of its pathophysiology remains insufficiently understood. This study demonstrated that NUF2 was significantly overexpressed in PCa, with its elevated levels correlating with poor patient survival outcomes. Silencing NUF2 notably impaired PCa cell proliferation and metastasis in both in vitro and in vivo models, whereas its overexpression promoted these processes. Additionally, YY1 was identified as a direct transcriptional activator of NUF2, binding to its promoter and enhancing its oncogenic effects through activation of downstream targets. Moreover, NUF2 promoted PCa progression by recruiting p38, accelerating its phosphorylation, and activating the p38/MAPK signaling pathway. Through the PubChem database, fisetin was identified as a small molecule inhibitor of NUF2. Fisetin effectively inhibited PCa cell proliferation, and NUF2 overexpression reversed this inhibitory effect. In conclusion, our results suggest that NUF2 overexpression accelerated PCa progression via the p38/MAPK pathway, regulated by YY1. The identification of fisetin as a NUF2 inhibitor offers a promising therapeutic strategy for targeting NUF2 to impede PCa growth. NUF2 may thus serve as a valuable prognostic biomarker and a potential therapeutic target for PCa.

2025-06-01·FOOD MICROBIOLOGY

Enhancing the quality of dark tea through fermentation with Aspergillus niger: Unveiling aroma and taste characteristics

Article

作者: Li, Maoyun ; Xiao, Yue ; Wu, Yanping ; Zhong, Kai ; Huang, Yina ; Gan, Renyou ; Gao, Hong ; Du, Sicheng

Amidst the increasing demand for premium dark tea, the utilization of Aspergillus niger-inoculated fermentation has emerged as a potential solution to address the challenges associated with extended processing cycles and inconsistent quality. This study comprehensively investigated the efficacy and mechanisms of A. niger PW-2 inoculation in enhancing dark tea quality compared to spontaneous fermentation, using metabolomics, electronic tongue, molecular docking, and high-throughput sequencing. A. niger PW-2 shaped the fungal community within 7 days, degrading terpene glycosides and lactones while generating terpenoids and unsaturated fatty acids, which enriched the floral aroma of PW-2-inoculated fermentation dark tea (AF). Flavonoid degradation and reduced theaflavins/thearubigins levels in AF decreased astringency, while increased bitter dipeptides and isoflavonoids enhanced bitterness, and the accumulation of umami dipeptides and theabrownins improved umami taste perception of AF. Molecular docking identified key compounds responsible for astringency (kaempferol glycosides), bitterness (6″-caffeoylisoorientin, kaempferol 4'-glucoside 7-rhamnoside, dihydrodaidzein 7-O-glucuronide), and umami (3-O-p-trans-coumaroylalphitolic acid, dihydrodaidzein 7-O-glucuronide, 1-methoxyphaseollidin). Overall, A. niger PW-2 inoculation accelerates fermentation process and enhances flavor characteristics of dark tea, offering a promising approach for high-quality dark tea production.

项与漆黄素相关的新闻（医药）

2025-01-09

·Business Wire

Bonerge Announces the New 108 Person Clinical Trial: Exploring Skin and Organ Anti-Aging Innovations

NEW YORK--( BUSINESS WIRE )--Bonerge announced the initiation of its clinical trial, focusing on Fisetin, Urolithin A, and Ergothioneine. Involving 108 participants, this trial aims to evaluate their combined effects on skin health and organ rejuvenation when taking orally, providing more reliable options for the market. Senolytics Research: Advancing the Science of Anti-Aging In recent years, Senolytics research has advanced rapidly, with institutions like the Mayo Clinic and Wake Forest University at the forefront. Despite fruitful research, identifying optimal applications to translate Senolytics into market solutions remains crucial. In October 2024, the Mayo Clinic published groundbreaking findings in Nature Aging, identifying 67 plasma proteins, with IL-23R emerging as a promising anti-aging biomarker 1 . The study explored various promising Senolytics, including Fisetin, demonstrating a positive response in reducing senescence-related proteins and indicating potential for organ rejuvenation via senescent cell clearance 2 . The concept of organ rejuvenation offering deeper insights into its systemic effects and guiding anti-aging strategies. Senolytics show strong potential for organ rejuvenation applications and promise broader future prospects. Bonerge’s Clinical Trial: Exploring Skin as the Key to Rejuvenation The skin, the largest organ of the human body, is the most visible indicator of aging and a key target for anti-aging. Bonerge has launched a clinical trial focused on skin anti-aging, involving 108 participants. The trial evaluates skin anti-aging effects by assessing factors like skin heme, skin inflammation, transepidermal water loss, wrinkles, skin elasticity, skin firmness, melanin levels, and skin tone. Spanning 56 days, it aligns with two skin regeneration cycles, providing a detailed analysis of these key skin health indicators. Three ingredients tested in the trail: Fisetin: Among natural ingredients, fisetin has the strongest activity in clearing senescent cells. Its core mechanism promotes apoptosis of senescent cells and reduces SASP (Senescence-Associated Secretory Phenotype) secretion, alleviating chronic inflammation and combating inflammaging 3 , contributing to organ rejuvenation. Urolithin A: A rising star in nutritional supplements, Urolithin A has shown significant anti-photoaging effects. Photoaging, primarily caused by UVA (ultraviolet A) radiation, accelerates skin aging. Urolithin A helps protect skin by reducing the senescent phenotype of skin fibroblasts triggered by UVA, lowering intracellular ROS (reactive oxygen species), and activating antioxidant enzymes. These actions collectively support skin health and combat the harmful effects of photoaging 4 . Ergothioneine : Currently recognized as the only antioxidant that targets mitochondria, it reduces oxidative damage within mitochondria, supporting energy production and potentially preventing cellular aging 5 . Key Focus: Exploring Individual Ingredients and Combined Synergies In this clinical trial, while examining the skin anti-aging effects of individual ingredients, the combination of the three ingredients have also been tested to explore the synergistic effects on skin health and anti-aging. Path Ahead: Trial Progress and Future Expectations The clinical trial is progressing as planned and is expected to conclude in March 2025. Bonerge is hopeful that this study will provide valuable evidence for the anti-aging market, paving the way for the application of Senolytics in skin health and broader anti-aging treatments. References [1] Chase M. Carver, et al. IL-23R is a senescence-linked circulating and tissue biomarker of aging. Nature Aging, Dec 2024. [2] Researchers discover an aging and inflammation biomarker - Mayo Clinic News Network [3] Matthew J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36 (2018). [4] Wenjie Liu , et al. Urolithin A protects human dermal fibroblasts from UVA-induced photoaging through NRF2 activation and mitophagy. J Photochem Photobiol B. 2022 Jul. [5] Brown, Lisa, et al. L-Ergothioneine and Its Protective Role in Cellular Health. Journal of Clinical Nutrition, vol 56.

临床研究

2024-12-31

·Business Wire

BeFisetin® is Gaining the First Fisetin Ingredient SA-GRAS Certification

NEW YORK--( BUSINESS WIRE )--In 2024, Bonerge's premium fisetin branded ingredient, BeFisetin®, initiated the SA-GRAS (Self-Affirmed Generally Recognized As Safe) certification process, with completion expected in February 2025. This certification underscores Bonerge's unwavering commitment to product safety, quality control and serves as a key milestone in its expansion into the global fisetin market. Fisetin: The Anti-aging Potential of Natural Polyphenols Fisetin is a natural polyphenol widely present in various fruits and vegetables such as strawberries, apples, and persimmons. In recent years, the scientific community's enthusiasm for exploring fisetin has been continuously rising. Numerous research findings have revealed that fisetin has unique biological properties in reducing inflammatory factors, strengthening cell health, and delaying aging [1-3], and its related applications have also attracted extensive and in-depth attention. Biochemical studies have shown that fisetin can exert its effects through multiple mechanisms. It can effectively reduce senescent cells in the brain, skin, and various organs, regulate inflammatory factors, and scavenge free radicals [4]. This makes fisetin an attractive dietary supplement, showing broad application prospects in healthy aging and long-term health management. BeFisetin®: Marketing Strategy and Innovation As a company dedicated to the development and research of high-quality ingredients, Bonerge recognizes the growing global demand for safe and effective dietary supplements. It is Bonerge’s principle to leverage cutting-edge science to transform advanced research into practical health solutions. Bonerge is continuously improving the purity and bioavailability of BeFisetin®, while integrating sustainable production practice, demonstrating a strong commitment to environmental responsibility. Focusing on the great potential of fisetin, Bonerge has engaged in in-depth strategic collaborations with multiple research institutions and universities to strengthen the scientific validation and credibility of BeFisetin®, continuously enhancing its trust and reputation through rigorous scientific verification. This ensures consumers have access to transparent, reliable health solutions. SA-GRAS Certification: An Extended Standard in Safety and Trust SA-GRAS certification, a critical extension of the FDA's GRAS framework, allows companies to confirm the safety of their products through rigorous self-assessment. This process involves establishing stringent product standards, conducting comprehensive toxicity and safety evaluations, and systematically assessing raw materials, manufacturing processes, and product stability. Companies need to work with independent professional organizations to prepare detailed safety assessment reports, which are reviewed by an expert panel. The rigorous certification process drives Bonerge to further optimize its product quality systems and elevated BeFisetin®'s competitiveness in the global market. For Bonerge, SA-GRAS certification is not merely a regulatory milestone but a testament to its relentless pursuit of product excellence and its commitment to consumer safety. Looking Ahead: Responsibility and Opportunity The expansion of aging population is a global challenge, driving increasing demand for health-focused anti-aging solutions. Bonerge is committed to leveraging BeFisetin®'s superior quality to advance scientific research, foster innovation, and provide consumers with safer and trustworthy products. To be or not to be, that is the question! BeFisetin®: A scientific breakthrough as the world’s first SA-GRAS-certified fisetin ingredient, setting a new industry standard. References [1] Yoon S, Lee H, Kim J, et al. A natural flavonoid, fisetin, alleviates neuroinflammation and memory impairment in D-galactose-treated mice[J]. Frontiers in Pharmacology, 2023, 14: 1134733. [2] Li X, Zhang H, Guo Y, et al. Fisetin promotes osteoblastogenesis and inhibits adipogenesis in bone marrow stromal cells through the activation of the Wnt/β-catenin pathway[J]. International Journal of Molecular Sciences, 2019, 20(23): 5957. [3] Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan[J]. EBioMedicine, 2018, 36: 18-28. [4] Takaya K, Kawaguchi M, Mizutani K, et al. Fisetin, a potential skin rejuvenation drug that eliminates senescent cells in the dermis[J]. Biogerontology, 2023, 24(5): 409-421.

2024-12-17

·生物世界

Nature Aging：梅奥医学中心发现新型衰老标志物——IL-23R

撰文丨王聪编辑丨王多鱼排版丨水成文细胞衰老是一种以细胞周期停滞和衰老相关分泌表型（SASP）为特征的衰老机制。临床前研究表明，靶向衰老细胞生存通路的抗衰老药物可对抗多个器官的年龄相关疾病。尚未有任何研究证实不同类型的衰老细胞清除药物在体内对改变衰老和衰老标志物的相对有效性。 2024年12月10日，梅奥医学中心的研究人员在 Nature Aging 期刊发表了题为：IL-23R is a senescence-linked circulating and tissue biomarker of aging 的研究论文。该研究表明，白细胞介素-23受体（IL-23R）是一种衰老相关的循环和组织生物标志物。细胞衰老是一种年龄相关机制，参与多种器官系统的发病，包括免疫功能障碍、心血管和代谢性疾病、肺纤维化、骨质疏松、肾脏疾病、肝损伤、肌肉减少症和认知功能下降等。衰老血液中的因子可驱动许多组织的衰老和炎症激活。但早衰循环因子的组织和细胞特异性起源尚未明确。来源于衰老细胞的循环蛋白可能反映全身衰老细胞负荷，可能被开发为诊断或预后生物标志物，并且可能是早衰器官间通讯的介质。在这项最新研究中，研究团队建立了衰老和衰老相关的血浆蛋白和组织转录物，它们在老年和年轻的小鼠中发生了变化。研究团队在老年p16-InkAttac小鼠中研究了Venetoclax（一种Bcl-2抑制剂）、Navitoclax（一种Bcl-2抑制剂）、fisetin（漆黄素）或luteolin（木犀草素）急性治疗与转基因衰老细胞清除之间的反应。结果显示，年龄依赖性的血浆蛋白变化，包括IL-23R、CCL5和CA13，被治疗药物逆转，这对应于组织的表达差异，特别是在肾脏。而在人的一生中，血浆中IL-23R随着年龄的增长而增加。这些结果揭示了循环因子作为与衰老相关的器官间信号转导的候选介质和全身衰老细胞负荷的生物标志物。论文链接： https://www-nature-com.libproxy1.nus.edu.sg/articles/s43587-024-00752-7 设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

100 项与漆黄素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB07795

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
系统性硬化相关的间质性肺病	临床2期	美国	Mayo Clinic	2023-04-12
腕管综合征	临床2期	美国	Mayo Clinic	2022-10-09
新冠肺炎后遗症	临床2期	美国	Mayo Clinic	2020-08-03
Crouzon综合征伴黑棘皮症	临床2期	美国	Mayo Clinic	2018-02-06
炎症	临床2期	美国	Mayo Clinic	2018-02-06
肾纤维化	临床前	中国	四川大学华西医院（四川省国际医院）	2023-03-01
黑色素瘤	临床前	美国	University of Wisconsin Madison	2013-04-15
前列腺癌	临床前	美国	University of Wisconsin Madison	2009-05-01
结肠癌	临床前	美国	University of Wisconsin Madison	2008-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AACR2025	N/A	胰腺导管腺癌 CD44 \| CD24 \| CD133 ... 更多	-	Fisetin	艱蓋築鬱壓憲糧夢簾餘(築簾鬱築網夢簾衊鹽鹹) = 衊醖糧膚簾觸鑰膚獵獵築鹹夢膚願鹹範鏇壓獵 (簾鹹鏇壓糧選憲構淵鬱 )	-	2025-04-27
				Fisetin (Untreated)	艱蓋築鬱壓憲糧夢簾餘(築簾鬱築網夢簾衊鹽鹹) = 艱艱膚鬱鹹廠鹽觸廠憲築鹹夢膚願鹹範鏇壓獵 (簾鹹鏇壓糧選憲構淵鬱 )
NCT04210986 (CTgov)	临床1/2期	膝关节炎	75	Fisetin (Fisetin)	製齋淵蓋糧艱鑰觸淵蓋 = 鹽築顧壓齋構壓願簾選範窪構襯遞鏇糧顧觸築 (鬱選範齋齋蓋膚鏇淵鏇, 窪觸鬱範鹹構簾繭衊簾 ~ 鹽艱獵網膚積鏇網醖淵) 更多	-	2024-09-19
				Placebo oral capsule (Placebo)	製齋淵蓋糧艱鑰觸淵蓋 = 觸選構廠願淵網鑰廠醖範窪構襯遞鏇糧顧觸築 (鬱選範齋齋蓋膚鏇淵鏇, 壓積壓築糧窪夢遞壓獵 ~ 選齋鏇夢顧艱廠壓築淵) 更多
NCT04771611 (COVFIS-HOME, CTgov)	临床2期	新型冠状病毒感染	55	Fisetin (Treatment Group)	範憲窪鹹鹽壓鏇觸壓構 = 觸築夢鏇蓋製廠遞製膚構壓膚憲醖築遞窪淵淵 (築艱築蓋範廠窪鬱鹽繭, 壓艱鏇艱淵鹹鹹獵鹹艱 ~ 鏇衊膚觸廠顧衊獵齋築) 更多	-	2023-08-01
				Placebo (Placebo)	範憲窪鹹鹽壓鏇觸壓構 = 壓製鹹構壓製鹹醖獵觸構壓膚憲醖築遞窪淵淵 (築艱築蓋範廠窪鬱鹽繭, 鹹餘簾壓遞憲淵獵膚壓 ~ 製願獵獵糧糧鑰鏇鹽願) 更多